CONTROL OF INVASIVE PULMONARY ASPERGILLOSIS WITH ORAL ITRACONAZOLE IN A BONE-MARROW TRANSPLANT PATIENT

Pulmonary aspergillosis following bone marrow transplantation carries a mortality of 94%, irrespective of current treatment. We treated a patient who had acquired aspergillosis some 80 days after allogencic bone marrow transplantation, with oral itraconazole, 600 mg daily. After initial deterioration, clinical and radiographic resolution occurred during 3 months of therapy despite severe graft-vs.-host and cytomegalovirus disease. Itraconazole should be considered for therapy of pulmonary aspergillosis in this and other immunocompromised settings. © 1992 The British Society for the Study of Infection.